𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I–II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia

✍ Scribed by Mailliard, James A. ;Letendre, Louis ;Dalton, Robert J. ;Levitt, Ralph ;Gerstner, James B. ;Therneau, Terry M. ;Pierre, Robert V.

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
442 KB
Volume
14
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

VP-16 was used to treat newly diagnosed elderly ( 2 6 5 yr) patients with acute nonlymphocytic leukemia (ANLL) and patients with blast crisis of chronic granulocytic leukemia (BI-CGL). Our pilot study indicated that VP-I6 160 mg/m2 intravenously daily for 5 days was well tolerated and suggested a direct doseresponse correlation. Thirty additional ANLL patients and 11 CGL patients were studied. Among 26 evaluable ANLL patients, we observed ten responses (38%) (seven complete remission and three partial remission), but none of 11 patients with CGL in blast crisis

📜 SIMILAR VOLUMES

VP 16–213 and cyclophosphamide in the tr
VP 16–213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features
✍ Hurd, David D. ;Peterson, Bruce A. ;McKenna, Robert W. ;Bloomfield, Clara D. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

## Abstract The treatment of refractory acute nonlymphocytic leukemia remains a major clinical problem in leukemia therapy. VP 16–213 is an investigational agent that may have specificity for monocytic blasts, and the combination of VP 16–213 and cyclophosphamide is synergistic in experimental leuk

Phase I study of VP-16 (etoposide) and a
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia
✍ Letendre, Louis ;Hinemann, Vicky ;Hoagland, H. Clark ;Kovach, John S. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Fourteen patients with refractory acute nonlymphocytic leukemia were entered into a doseseeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial rem

Autopsy study of blast crisis in patient
Autopsy study of blast crisis in patients with chronic granulocytic leukemia, Hiroshima and Nagasaki, 1949–1969
✍ Paul I. Liu; Toranosuke Ishimaru; Douglas H. McGregor 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB 👁 1 views

This report examines the relation of blast crisis to whole body radiation a t the time of the atomic b o m b (ATB), and describes the autopsy findings in 23 cases of CGL with terminal blast crisis f o u n d among 101 CGL cases autopsied in Hiroshima and Nagasaki, Japan, d u r i n g the period 1949-1

Treatment of refractory acute myeloid le
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: Results of a clinical phase I/II study
✍ Wolfgang Hiddemann; Dieter Urbanitz; Peter Preusser; Wolf Achterrath; Thomas Büc 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

Twenty patients with refractory AML were treated with mAMSA and VP 16-2 13 in combination to assess the toxicity and anti-leukemic activity of the two-drug regimen. Refractoriness was defined according to the response to induction therapy consisting of 6-thioguanine, cytosine arabinoside and daunoru

Meningeal relapse in Ph1-positive acute
Meningeal relapse in Ph1-positive acute lymphoblastic and lymphoid blast crisis of chronic granulocytic leukemia. Is CNS-prophylaxis indicated?
✍ Dr. Alastair G. Smith; Archibald G. Prentice; Norman P. Lucie; John H. Dagg 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB 👁 2 views

Two cases of Phi-positive acute lymphoblastic leukemia (ALL) and one case of lymphoid blast crisis (LyBc) of chronic granulocytic leukemia (CGL) treated with standard chemotherapy for ALL are presented. Hematologic remissions lasting 6, 12, and 15 months were achieved in all cases. Meningeal relapse